Lupus anticoagulant in human immunodeficiency virus–infected patients on highly active antiretroviral therapy
| dc.contributor.author | Awodu, O.A. | |
| dc.contributor.author | Olayemi, E.E. | |
| dc.contributor.author | Bazuaye, G.N. | |
| dc.contributor.author | Onunu, A.N. | |
| dc.date.accessioned | 2012-05-16T12:22:03Z | |
| dc.date.accessioned | 2017-10-19T11:54:25Z | |
| dc.date.available | 2012-05-16T12:22:03Z | |
| dc.date.available | 2017-10-19T11:54:25Z | |
| dc.date.issued | 2010 | |
| dc.description.abstract | Lupus anticoagulant (LA) is a heterogeneous group of antibodies that causes a variety of clinical and laboratory effects; has been described in infections such as human immunodeficiency virus. LA has not been previously described in Nigerians with human immunodeficiency virus infection on highly active antiretroviral therapy (HAART). | en_US |
| dc.identifier.uri | http://197.255.68.203/handle/123456789/1394 | |
| dc.language.iso | en | en_US |
| dc.publisher | Indian J Pathol Microbiol 53(1): 47-9 | en_US |
| dc.title | Lupus anticoagulant in human immunodeficiency virus–infected patients on highly active antiretroviral therapy | en_US |
| dc.type | Article | en_US |